Company: MYGN
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0000899923-25-000048
Chunk: 34

Company: MYRIAD GENETICS INC
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
 at the same level as presented in Consolidated Statement Operations in these financial statements. 

14.SUPPLEMENTAL CASH FLOW INFORMATION

The Company's supplemental cash flow information for the three months ended March 31, 2025 and 2024 are as follows:Three Months Ended March 31,(in millions)20252024Cash paid for income taxes$0.3 $— Cash paid for interest0.5 0.2 Non-cash investing and financing activities: Change in operating lease right-of-use assets and lease liabilitiesOperating lease right-of-use assets$1.2 $(0.3)Operating lease liabilities(1.2)(3.1)Purchases of property, plant, and equipment and capitalization of internal-use software in accounts payable and accrued liabilities4.2 4.5 

17

Table of Contents

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows.March 31,(in millions)20252024Cash and cash equivalents$91.8 $96.9 Restricted cash9.2 8.7 Total cash, cash equivalents, and restricted cash$101.0 $105.6 

15. ACCUMULATED OTHER COMPREHENSIVE LOSS

The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders’ equity.The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss:

(in millions)Ending balance December 31, 2024$0.8 Period translation adjustments(0.2)Ending balance March 31, 2025$0.6                                                     

18

Table of Contents

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the related notes thereto included in this Quarterly Report on Form 10-Q and the audited Consolidated Financial Statements and related notes thereto and Management’s